| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
Form 4: Blackburn Kelly, EVP, Clinical Development
Granted 19,100 Stock Option (Right to Buy) |
| 23 Oct 2026 |
Form 4: De Rosch Mark, EVP, RA and GA and PgM
Granted 19,100 Stock Option (Right to Buy) |
| 23 Oct 2026 |
Form 4: Winton Matthew, Chief Commercial and Business
Granted 19,100 Stock Option (Right to Buy) |
| 14 Oct 2026 |
8-K: Regulation FD Disclosure
Certain information concerning the business, clinical studies, development plans, financial position, and related matters of CervoMed Inc. (the “Company,” “we,” or “us”) is being made available on our website, www.cervomed.com, under the... |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026 |
| 09 Oct 2026 |
8-K: Regulation FD Disclosure
Certain information concerning the business, clinical studies, development plans, financial position, and related matters of CervoMed Inc. (the “Company,” “we,” or “us”) is being made available on our website, www.cervomed.com, under the... |
| 28 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit |
| 10 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G |
| 10 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 07 Aug 2026 | FORM S-8 |
| 07 Aug 2026 | FORM 10-Q |
| 04 Aug 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 14 Jul 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 10 Jul 2026 | EFFECT |
| 10 Jul 2026 | FORM 424B3 |
| 09 Jul 2026 | 8-K: Regulation FD Disclosure; Other Events |
Loading...
